Petrelintide-matching Placebo

Phase 2

Petrelintide-matching Placebo is one of 3 therapeutic programs targeting Obesity or Overweight. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Obesity or OverweightNot yet recruiting

Obesity or OverweightPhase 2

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Obesity or Overweight

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Amgen

Phase 3

1 2

Petrelintide

Zealand Pharma

Phase 2

1 3

Petrelintide-matching Placebo

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Obesity or Overweight

NCT07589686

Clinical

Trials by Indication[1]

Obesity or Overweight1 trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight

Not yet recruiting· Roche logo

Roche·Phase 2·NCT07589686·486 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Petrelintide-matching Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Petrelintide-matching Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Roche

Petrelintide-matching Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Obesity or Overweight1 trial

References

Drug Info

Quick Facts

Related News